Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits

Lilly is the only FDA-approved company to legally sell products containing tirzepatide

- PMLiVE

Sanofi and Ad Scientiam partner to assess MS disability progression

The study will evaluate the ability of MSCopilot to identify early signs of disability worsening

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

- PMLiVE

Boehringer sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for selected medicines

- PMLiVE

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases in the US

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by CDC advisory committee for infants

Beyfortus will be available in the US ahead of the upcoming RSV season

- PMLiVE

Scleroderma Research Foundation launches clinical trial platform to advance treatments

The initiative will initially focus on interstitial lung disease secondary to scleroderma but will be expanded to address other manifestations of the disease

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links